Autoinflammatory & rare systemic diseases
Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis
Authors' conclusion
Anti-IL-1 agents were effective and demonstrated a low adverse event profile in paediatric and adult FMF patients.
Study context
- Population
- Adult and paediatric FMF patients who received continuous treatment with at least one anti-IL-1 drug (anakinra, canakinumab, rilonacept); databases screened from inception to May 2023
- Participants
- 1,399 Fourty-four reports
- Comparison
- Anti-IL-1 agents in adult and paediatric FMF
- Outcome
- Proportion of patients achieving complete remission of attacks
Methodological detailsrandom-effects meta-analysis
- Random-effects meta-analysis
Pooled result
As reported in the abstract
Complete remission of attacks
Further pooled results
- Anti-IL-1 agents significantly decreased levels of inflammatory markers
Safety
| Outcome | Adult | Paediatric |
|---|---|---|
| At least one adverse event during treatment (primary safety outcome) | 25% (95% CI 13%–37%) | 12% (95% CI 3%–21%) |
Original publication
Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis. Rheumatology (Oxford). Published 28 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →